The outcome of cross-priming during virus infection is not directly linked to the ability of the antigen to be cross-presented

被引:7
作者
Alatery, Attiya [1 ]
Tarrab, Esther [2 ]
Lamarre, Alain [2 ]
Basta, Sameh [1 ]
机构
[1] Queens Univ, Dept Microbiol & Immunol, Kingston, ON K7L 3N6, Canada
[2] Inst Natl Rech Sci, Inst Armand Frappier, Immunovirol Lab, Laval, PQ, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Antigen presentation/processing; Peptides/epitopes; Viral antigens; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; T-CELL RESPONSES; MHC CLASS-I; DENDRITIC CELLS; VIRAL PROTEIN; IMMUNODOMINANCE HIERARCHIES; EXOGENOUS ANTIGENS; MACROPHAGES; EPITOPE; IMMUNOPROTEASOMES;
D O I
10.1002/eji.200939973
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The initiation of CD8(+) T cell (CTL) immune responses can occur via cross-priming. Recent data suggested a relationship between cross-presentation and immunodominance of epitope-specific T cells. To test this association, we evaluated the efficacy of cross-presentation for several virus epitopes in vitro and examined if this can be extrapolated in vivo. Employing lymphocytic choriomeningitis virus (LCMV), we demonstrate that the cross-presentation and cross-priming of LCMV antigens were dominated by NP396, but not NP205 when analyzing the LCMV-NP. Although with LCMV-GP, cross-presentation was dominated by GP276, and cross-priming was dominated by GP33. Importantly, although NP396 was significantly more efficient than GP33 in cross-presentation, cross-priming of their specific CTL was comparable. In a subsequent virus challenge after cross-priming, GP33-specific CTL dominated the response. Accordingly, based on our data, the ability of viral epitopes to be cross-presented in vitro does not entirely reflect what would occur in cross-priming. Thus, weak cross-presenting antigens may still cross-prime an efficient CTL response depending on other in vivo elements such as the nave T-cell precursor frequencies.
引用
收藏
页码:2190 / 2199
页数:10
相关论文
共 37 条
[1]   An efficient culture method for generating large quantities of mature mouse splenic macrophages [J].
Alatery, Attiya ;
Basta, Sameh .
JOURNAL OF IMMUNOLOGICAL METHODS, 2008, 338 (1-2) :47-57
[2]   Cross, but not direct, presentation of cell-associated virus antigens by spleen macrophages is influenced by their differentiation state [J].
Alatery, Attiya ;
Siddiqui, Sarah ;
Chan, Matthew ;
Kus, Agnieszka ;
Petrof, Elaine O. ;
Basta, Sameh .
IMMUNOLOGY AND CELL BIOLOGY, 2010, 88 (01) :3-12
[3]   Phenotypic analysis of antigen-specific T lymphocytes [J].
Altman, JD ;
Moss, PAH ;
Goulder, PJR ;
Barouch, DH ;
McHeyzerWilliams, MG ;
Bell, JI ;
McMichael, AJ ;
Davis, MM .
SCIENCE, 1996, 274 (5284) :94-96
[4]   Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus [J].
Basler, M ;
Youhnovski, N ;
van den Broek, M ;
Przybylski, M ;
Groettrup, M .
JOURNAL OF IMMUNOLOGY, 2004, 173 (06) :3925-3934
[5]   The cross-priming pathway: A portrait of an intricate immune system [J].
Basta, S. ;
Alatery, A. .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2007, 65 (04) :311-319
[6]   Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins [J].
Basta, S ;
Stoessel, R ;
Basler, M ;
van den Broek, M ;
Groettrup, M .
JOURNAL OF IMMUNOLOGY, 2005, 175 (02) :796-805
[7]   QUANTIFICATION OF LYMPHOCYTIC CHORIOMENINGITIS VIRUS WITH AN IMMUNOLOGICAL FOCUS ASSAY IN 24-WELL OR 96-WELL PLATES [J].
BATTEGAY, M ;
COOPER, S ;
ALTHAGE, A ;
BANZIGER, J ;
HENGARTNER, H ;
ZINKERNAGEL, RM .
JOURNAL OF VIROLOGICAL METHODS, 1991, 33 (1-2) :191-198
[8]   MODE OF REPLICATION OF LYMPHOCYTIC CHORIOMENINGITIS VIRUS IN PERSISTENTLY INFECTED CULTIVATED MOUSE L CELLS [J].
BRUNS, M ;
KRATZBERG, T ;
ZELLER, W ;
LEHMANNGRUBE, F .
VIROLOGY, 1990, 177 (02) :615-624
[9]   Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses [J].
Chen, WS ;
Antón, LC ;
Bennink, JR ;
Yewdell, JW .
IMMUNITY, 2000, 12 (01) :83-93
[10]  
DEBRICK JE, 1991, J IMMUNOL, V147, P2846